Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Oct
2
2020
FDA’s Proposed Rule on “Intended Use” Confirms Agency Will Rely on “Any Relevant Source” of Evidence Sheppard, Mullin, Richter & Hampton LLP
Dec
4
2020
Cannabis Gets Go-Ahead from House, But Still Faces Hurdles Before Federal Legalization Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2010
The FDA Transparency Initiative: Another One Way Street? Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2021
“Buy American” Update: Essential Medicines May Continue to Come From Abroad (For Now) Sheppard, Mullin, Richter & Hampton LLP
Mar
13
2018
Under the Radar Changes to Proposition 65 – OEHHA Issues New “Guidance” For Web Purchases (Is it an Illegal “Underground Regulation”?) Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2013
No Avoiding BPCIA (Biologics Price Competition and Innovation Act) For Biosimilars: No Patent Declaratory Judgment Action Before Biosimilars Application Is Filed Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2022
FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Jan
16
2014
Contaminated but Remediated Soil and Cortese Listing Does Not Compel Preparation of EIR (Environmental Impact Report) Sheppard, Mullin, Richter & Hampton LLP
Jun
12
2014
Proposed Health Information Technology Strategy Aims to Promote Innovation Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2019
Don’t Spill Your Trade Secrets: Protecting Your Competitive Advantage in the Food and Beverage Industry (Part 1 of 2) Sheppard, Mullin, Richter & Hampton LLP
Jul
23
2019
Don’t Spill Your Trade Secrets: Protecting Your Competitive Advantage in the Food and Beverage Industry (Part 2 of 2) Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2022
California’s Newly Adopted “Safe Harbor” Warning Label for Acrylamide In Foods Turns Up the Heat In Ongoing First Amendment Challenge to Proposition 65 Sheppard, Mullin, Richter & Hampton LLP
Jan
20
2023
FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2023
CMS Releases First Set of Part B Rebatable Drugs for Coinsurance Adjustment Under IRA Sheppard, Mullin, Richter & Hampton LLP
Jun
15
2023
Access to Abortion Pill on the Precipice: A Deep Dive into the Federal Court Rulings that will Decide the Fate of Mifepristone Sheppard, Mullin, Richter & Hampton LLP
Feb
3
2020
Intellectual Property Outlook: Cases and Trends to Follow in 2020 — PART 2 Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Postpones Ex-US Facility Inspections Sheppard, Mullin, Richter & Hampton LLP
Apr
14
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies (as of April 14) Sheppard, Mullin, Richter & Hampton LLP
Nov
13
2023
CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule Sheppard, Mullin, Richter & Hampton LLP
May
27
2020
Impact Of COVID-19 On Illinois Cannabis Contracts — Do Force Majeure Clauses Provide A Defense To Non-Performance Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2020
Using ADR for Cannabis Disputes Sheppard, Mullin, Richter & Hampton LLP
Sep
25
2020
FDA Update: The Latest on Vaccine Development, Inspections, and Conducting Clinical Trials During Covid-19 Sheppard, Mullin, Richter & Hampton LLP
Nov
2
2020
The U.S. Court of Appeals Denies Rehearing on Cuts to 340B Drug Pricing Program Sheppard, Mullin, Richter & Hampton LLP
Jul
24
2010
FDA's Regulation of Laboratory Developed Tests (LDTs) - Changes on Horizon? Sheppard, Mullin, Richter & Hampton LLP
Nov
7
2010
United States Weighs in on Myriad Genetics Case Sheppard, Mullin, Richter & Hampton LLP
Jun
21
2013
Failure To Separately Notice Consideration Of California Environmental Quality Act (CEQA) Document Violates Brown Act Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2021
California Jury Awards Millions to Cannabis Company in Antitrust Case Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins